SCHEMBL5773095

SCHEMBL5773095

Cc1ccc(N2CCN(C(=O)C(Cc3ccc(O)cc3)N(C)C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP2C19 P33261 1/20 0.49
P2RX7 Q99572 2/20 0.45
ADORA1 P30542 1/20 0.45
MAPT P10636 4/20 0.44
GAA P10253 3/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
GCGR P47871 1/20 0.43
GPR119 Q8TDV5 1/20 0.42
ME2 P23368 4/20 0.41
ME1 P48163 4/20 0.41
ME3 Q16798 4/20 0.41
GFER P55789 1/20 0.41
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745397 1.00 SMN1; SMN2 (0.49) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5747764 0.91 ADORA1 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5744094 0.91 ADORA1 (0.52) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5746665 0.91 ME2 (0.50) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5747758 0.91 ADORA1 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5744099 0.91 ADORA1 (0.52) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5746583 0.91 P2RX7 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5746671 0.91 ME2 (0.50) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5746587 0.91 P2RX7 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7
SCHEMBL5767079 0.90 P2RX7 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487449-A4 TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS KING PHARMACEUTICALS RES & DEV (US) 2006-08-23 EP claimed
US-7094895-B2 Tyrosyl derivatives and their use as P2X7 receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-08-22 US claimed
EP-1487449-A1 TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS King Pharmaceuticals Research and Development Inc. (US) 2004-12-22 EP claimed
US-20030181452-A1 Tyrosyl derivatives and their use as P2X7 receptor modulators CREDIT SUISSE AG 2003-09-25 US claimed
WO-2003059353-A1 TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2003-07-24 WO claimed
US-7094895-B2 Tyrosyl derivatives and their use as P2X7 receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-08-22 US disclosed
US-20030181452-A1 Tyrosyl derivatives and their use as P2X7 receptor modulators CREDIT SUISSE AG 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181452-A1 Tyrosyl derivatives and their use as P2X7 receptor modulators P2RX7, P2RX3, P2RX5 SMN1; SMN2 3550/4885MEN1 4670/4885KMT2A 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.